tirzepatide kidney stones Can GLP‑1 medications increase stone risk? A UAB urologist offers insight Abdominal pain - Nephrolithiasis -

Consider this post the context-setting for the 2026 Health Populi TrendCast which youll see next week

Coverage Baseline Previously unavailable under Medicare Part D Only 13 states cover them in Medicaid (KFF HMA survey) 19% of large employers cover GLP-1s for obesity, though 43% of employers with 5,000+ employees offer coverage (KFF 2025 survey) Current Expansion ~50% of CVS Caremark clients now provide coverage for weight loss Medicare GLP-1 Bridge program launches coverage for eligible Medicare Part D patients 7/1/26 This aligns with a recent survey from Business Group on Health that found 67% of the surveyed employers now cover GLP-1s for weight loss (though a reduction is expected for 2027)

By purchasing, you acknowledge this product is for research use only.

Tirzepatide shows front-line potential in type 2 diabetes with heart disease, per Lillys SURPASS-CVOT outcomes trial.

Discover what clinical trials reveal about cancer risk, FDA warnings on thyroid tumors, and when to contact your doctor about concerning symptoms.

Food and Drug Administration, several Wall Street analysts said.